Clinical Report: Shifts in Liver Failure Mortality Rates Among Adults with DSMTs

Overview

This study analyzes liver failure-related mortality trends among middle-aged and older adults with digestive system malignant tumors (DSMTs) in the U.S. from 1999 to 2023. Findings indicate a decline in mortality rates, although disparities persist across demographic and geographic groups.

Background

Digestive system malignant tumors (DSMTs) are a leading cause of cancer-related morbidity and mortality, particularly among older adults. As cancer survival rates improve, the impact of coexisting conditions like liver failure becomes increasingly significant. Understanding mortality trends related to liver failure in this population is crucial.

Data Highlights

Key Findings

• 82,796 liver failure-related deaths occurred among patients aged ≥45 years with DSMTs from 1999 to 2023.
• Annual deaths from liver failure declined by 21.33% from 1999 to 2023.
• The age-adjusted mortality rate (AAMR) decreased from 4.34 to 2.08 per 100,000 population.
• Mortality rates showed substantial heterogeneity, with males exhibiting higher rates than females.
• Marked increases in liver failure-related deaths were observed among Hispanic individuals.
• Geographic variations revealed uneven declines in mortality rates across different Census and HHS regions.

Clinical Implications

Healthcare providers should monitor liver function and assess risk for liver disease among patients with DSMTs, especially in high-risk demographic groups.

Conclusion

Liver failure-related mortality has declined among older adults with DSMTs, but disparities remain.

Related Resources & Content

1. The New Gastroenterologist, 2025 -- Mortality Rates from Hepatocellular Carcinoma Linked to Alcoholic Liver Disease Rise Significantly
2. Frontiers in Endocrinology, 2026 -- Mortality trends in diabetes with proxy-defined steatotic liver disease in the United States, 1999–2023
3. Frontiers in Gastroenterology, 2026 -- U.S.A. trends in intrahepatic and bile duct cancers from 1999–2023
4. Frontiers in Medicine, 2026 -- Prediction models for mortality in patients with acute on chronic liver failure: systematic review and critical appraisal
5. EASL-CLIF, NACSELD and APASL definitions for identification of acute-on-chronic liver failure and its outcome in a non-transplant setting - PubMed
6. New ESMO Clinical Guidelines for the diagnosis and treatment of hepatocellular carcinoma
7. EASL-CLIF, NACSELD and APASL definitions for identification of acute-on-chronic liver failure and its outcome in a non-transplant setting - PubMed
8. New ESMO Clinical Guidelines for the diagnosis and treatment of hepatocellular carcinoma
9. Clinical and dosimetric considerations for yttrium-90 glass microspheres radioembolization of intrahepatic cholangiocarcinoma, metastatic colorectal carcinoma, and metastatic neuroendocrine carcinoma: recommendations from an international multidisciplinary working group | European Journal of Nuclear Medicine and Molecular Imaging | Springer Nature Link